The company said that the agency had requested additional data for obeticholic acid and thus moved the upcoming advisory committee meeting from June 9 to June 26, thereby delaying its decision on approval, which had also been scheduled for June 26.

LEAVE A REPLY

Please enter your comment!
Please enter your name here